Genenta Science S.p.A. (the “Company”) announced that on January 20, 2023 the Company and AGC Biologics S.p.A. (“AGC Biologics”) have entered into a development and manufacturing services agreement (the “AGC Biologics MSA”) pursuant to which AGC Biologics will provide lentivirus vector (“LVV”) manufacture certain of the Company's drug products for its ongoing clinical programs (the “Services”). The AGC Biologics MSA establishes timelines for purchase order submissions and manufacturing date changes and cancellation. The AGC Biologics MSA also sets a timeline for the Services and for technology transfer if required and includes customary termination provisions, allowing for termination by a party upon the other party's uncured material breach or upon the other party's insolvency.

The Company will render payment to AGC Biologics for each stage reached by AGC Biologics while providing the Services to the Company. The Company has an existing manufacturing services agreement with Molecular Medicine S.p. A (which was subsequently acquired by AGC Biologics), dated March 6, 2019, pursuant to which AGC Biologics has agreed to manufacture the Company's LVV and drug product for the Company's ongoing clinical programs. The services provided under this existing agreement are in addition to the Services that will be provided under the AGC Biologics MSA.